- Home
- PMVP vs ASRT Comparison
PMVP vs ASRT Comparison
Compare PMVP & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PMVP | ASRT |
|---|---|---|
| Founded | 2013 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.0M | 75.1M |
| IPO Year | 2020 | 1997 |
Fundamental Metrics
Financial Performance| Metric | PMVP | ASRT |
|---|---|---|
| Price | $1.24 | $10.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $5.00 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 269.9K | 30.2K |
| Earning Date | 11-12-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $137,354,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 9.22 |
| 52 Week Low | $0.81 | $7.71 |
| 52 Week High | $1.84 | $15.15 |
Technical Indicators
Market Signals| Indicator | PMVP | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 47.47 | 98.16 |
| Support Level | $1.20 | $0.61 |
| Resistance Level | $1.25 | $0.75 |
| Average True Range (ATR) | 0.07 | 0.10 |
| MACD | 0.01 | 0.58 |
| Stochastic Oscillator | 70.27 | 94.90 |
Price Performance
Historical ComparisonAbout PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.